Skip to main content

ACR 2026: ILD Topic Panel

Nov 18, 2026 9:12 pm
What stood out in interstitial lung disease (ILD) at ACR 2026? Join Drs. Jack Cush, Elena Joerns, Janet Pope, and Daric Mueller, PA-C for RheumNow’s ILD Topic Panel Recap. The panel highlights research from Orlando and discusses what the findings could mean for rheumatologists caring for patients with ILD.

Transcription

This is an ACR 2026 podcast coming to you from ACR in Orlando. Hope you enjoy it.

This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.

Hello, everyone. This is RheumNow's recap of the meeting. Today, we're going to do a, review of what we thought were important abstracts on interstitial lung disease at ACR Convergence twenty twenty seven. I have a panel of experts who are out looking at this data as it was presented last week in Orlando, and we're going to cover at least, seven or eight of the abstracts that we thought were important. Let's begin with introductions.

I'm Jack Cush in Dallas, Texas. Janet?

Janet Pope, London, Ontario, Western University.

And Derek?

Hey, everyone. Derek Mueller, PA, Detroit, Michigan.

And Elena?

Hi. Elena Jerns, Rochester, Minnesota.

Okay. Let's begin with Elena. What what did you find to be really interesting last week at ACR?

Yeah. So there were quite a few interesting abstracts. So the first one I wanted to talk about was subgroup analysis of the myositis ILD in FibroNIR ILD trial. So again, that's a trial of Neurandomilast, which is a PDE4B inhibitor in ILD. And they had a subgroup of autoimmune patients, and thirty three was myositis.

So they were looking at whether there was any signal in those patients with administration of neurondomolasty, either at eighteen milligrams or nine milligrams. And they did find that there was a signal. There was a much less decline in FVC at the end of the trial in the eighteen milligram group, and also a sizably less decline in the nine milligram group. And the extent of the decline was better in the higher dose group. So that is very encouraging.

So both of those confidence intervals cross zero, so we cannot really make specific conclusions, but it does look encouraging for the patients with myositis ILD. And then another study that I wanted to talk to you guys about is abstract zero four thirty. So that was looking at study out of Brazil that looked at characteristics of Sjogren's associated ILD. So they had. So there were a couple of interesting things about that abstract.

They had hundred and eighteen patients with primary Sjogren's, and all of them underwent chest CT. They found actually that forty six of them had ILD, which is like forty four percent. So one, their ILD was very common in Sjogren's, which surprised me. Of course, it was a retrospective study, so, it could have been higher because they underwent, chest CTs. And then they found that older age was associated with higher odds of ILD, but low C4 and parotid involvement.

And also it looked like cryoglobulinemia were all associated with lower odds of ILD in Sjogren's. So they were kind of thinking that maybe there's a different mechanism that is causing the ILD and Sjogren's, not this classically B cell driven mechanism.

Doctor. So I want to ask first about the myositis report, and that is that, I've been impressed by, you know, a lot of the ILD literature and its association with, our many autoimmune diseases is scary, poor outcomes, you know, but that's why we have, you know, this major trend right now to research this, study this, develop new drugs for this, and all that's good. If if there's a subgroup that's looked good, it looked like it's the myositis group. And did that show up in this trial, or were the people that were severe enough to get into the FibroNir study so severe with their ILD associated with myositis, were they maybe better candidates like you might have seen from other studies before?

Yeah. In this FibroNir ILD study, they only included patients with progressive pulmonary fibrosis, which of course can sometimes be difficult in our diseases, because how are we defining the progressive pulmonary fibrosis as they're not being treated adequately. So yes, there might be some selection bias with those patients. And also, they weren't allowed a lot of background medications that we're seeing. So, I mean, maybe we're seeing that any treatment was better than minimal treatment in those patients.

It's hard to tell whether truly Neurandomolast was adding benefit to these patients. I believe from the FiberNeer ILD study, they didn't really see necessarily differences in signals between various autoimmune ILDs, but all the numbers were so low. And of course, there is a study that is going on right now. They recently actually completed recruitment of FibroNear SARD, where they are focusing on patients who were stable or declining. So we might get a little bit more answers whether neuroderma mass is truly helpful in addition to background immunosuppression, and also whether it's helpful in patients who are not actively progressing.

Can you define SAARD for our audience?

Yes, SAARD is a term introduced by ACR a couple of years ago, systemic autoimmune rheumatic disease. So we're not really... CTD is going out of fashion, folks. It's start in the ILD world.

So Janet, you deal with a lot of this in your scleroderma work and ILD studies. What do you look at this data? Is it really encouraging, these subset analyses or is it part of a bigger picture?

Both actually. So first of all, I'm really excited about the the fibrinir whole, for our kind of progressive pulmonary fibrosis patients because none of these are meant to look at the subset of the subset of the subset by a P value, but to look, are things going in the right direction? I think what has me most excited overall on Neurodolomast in the progressive pulmonary fibrosis non IPF, so SAARD patients and other reasons for that aren't IPF, is less hospitalizations, less time to clinical worsening, less bad outcomes. So I think it's pretty exciting, but if we go down, down, down on a subgroup of a subgroup of a subgroup kind of thing, if you don't get a p value, don't worry about it. Just say, is the treatment consistent or not with what I would expect and say the other SARDs, etcetera.

So I'm excited.

Yeah, I want to go to the second report. I too was surprised by the amount of ILD that was found retrospectively and maybe a little bit of a bias there. But, I don't usually think about screening Sjogren's for ILD. Derek, you're interested in this area. How do you handle who you screen for ILD?

I think with Sjogren's, it's a similar story to rheumatoid arthritis. Unless a patient has crackles or suggestive symptoms, it's not necessarily I'm going digging for. Just like with rheumatoid arthritis, we're gonna find interstitial lung abnormalities on many of these patients and we don't necessarily wanna go digging that up if it's not something that's actionable or if it's gonna result in some potential nonsense with their therapy, like a drug being withdrawn that maybe should not have been. I think there's a fine line in some of these diseases. I mean, I think certainly higher risk groups in myositis and systemic sclerosis definitely deserve much closer screening.

In Sjogren's, I don't think anyone is too sure on that.

Doctor. I'd like to get off on this tangent because I think it's important for the audience. What we've learned in the last few years with EULAR guidelines and a bunch of guidelines on ILD and screening, we're supposed to be screening more patients. The question is, are you going to be pragmatic like Derek and for ILD in people who either are at high risk or people who are symptomatic where then an intervention makes like a new treatment makes sense? Or should you screen and then make that a high risk patient after you've seen?

There was an abstract that you are said that if you screen all RA patients, without symptoms and whatnot, was it like seven percent had, ILD by, chest CT, high res chest CT screening. So Elena, you're really, you and Janet are really connected to this literature. I'd like to know your guidance for the audience on how we should be approaching screening.

Yeah. So, both ACR and EULAR kind of gave guidelines on who they consider, high risk, patients for ILD and Sjogren's. And they, both of them state older age, but ACR also includes row fifty two, ANA, Raynaud's, severe dental caries, and also lymphopenia. And then EULAR lists elevated inflammatory markers and active extrapulmonary involvement. So in that, this study kinda showed a little bit different, right?

So kind of different factors. They didn't really find anything that was increasing the risk besides the older age. Now, of those guidelines really gave these recommendations not based on, like, the risk to the patient necessarily, but more on the cost to the health care system. So, you know, for me, needs of the patients come first. So...

And I see so much ILD and so much ILD that went bad. I I will screen patients with Sjogren's most of the time for ILD at least once.

Interesting. And by that you mean CT as opposed I

mean CT.

Janet, how was your approach?

So my approach in Sjogren's is different than in scleroderma. In scleroderma, even myositis, I'm going to screen everybody. In Sjogren's, I usually wait for signs or symptoms and I realize that might be waiting too late. Like I listen to every SARD, I'll call them CTD formerly, patient's bases on every visit. Why not?

It takes four seconds to listen for crackles, yes or no. But so I will, it won't take much for me to investigate, but I must say there's there is no way even if I'm missing three quarters, there is no way that Sjogren's has that higher rate of ILD that's clinically relevant. So I don't want to pick up stuff that we have to deal with and we don't know what to do because they're asymptomatic and you don't know is it old scar. Obviously it's progressing, that's one thing. But people can have pneumonia and have a scar or something.

So that's the way I would think, but I realize we do see different kinds of patients.

Yeah, I think this is important because we have to have a firm story in our head about, what you're going to do with the results when you get them. Is it going to help you manage the patient in the long run? Again, better management of these patients could be a substantial savings to patient, the family, and, society in general. Let's move on. Derek, let's hear your two, abstracts that you thought were noteworthy from this meeting.

Alright. So the first is abstract sixteen seventeen by Banque et al. This is another subgroup analysis from that Fibronir ILD trial of progressive pulmonary fibrosis. I think it's important to look at this data in different ways because this is such a large population of SARD ILD patients that I think it makes sense to sift through this. A lot of this is hypothesis generating for sure and very interesting.

So again, within the FibroNir ILD trial, which was a very large trial, over 1,000 patients that included multiple forms of non IPF ILD, but our cohort of SARD patients made up about three twenty five. Of that, most of it was either rheumatoid arthritis, systemic sclerosis, and then a smattering of myositis, mixed connective tissue disease, and what have you. So, this specific subgroup analysis was interested in looking at the time of initial ILD diagnosis and if that made any kind of influence upon the efficacy of the intervention norandolamast. So, the subgroups looked at, we had a couple different categories, ILD diagnosis of equal or less than a year, one to three years, three to five years, and then five years plus. So, roughly this is busted up into quarters in each of those groups.

So, within the subgroup analysis, it did not appear that time since ILD diagnosis had any obvious detriment to the trend in FVC, decline, exacerbation risk, hospitalization or death. So, a lot of the things we care about, but with all the caveats of a subgroup analysis. But I think this is very interesting and understanding and appreciating that it might not be too late to use these drugs. They may have a role to play early on in the course of ILD and then potentially later on. But of course, we're potentially grappling with a different ratio of active inflammation to fibrosis depending on what disease we're looking at and what time period they were diagnosed.

So, the time to diagnosis was relative to their primary, SAR diagnosis, like relative to how many years into RA before they developed ILD. Is that what that was?

I believe it was actually the time to ILD within that rheumatic diagnosis, not necessarily since the diagnosis of RA, if I'm making sense there.

I'm just wondering, does that translate to trajectory or rapidity of disease. I don't know that it does because that I think is an important factor. How rapid that you change with your ILD has a lot to do with morbidity and mortality, but I don't know that this one does. But I think it does make the point that treatment may be appropriate at different time points. Janet, what do you think?

I agree. I think it's difficult. Not everything's cut and dry. So all purely fibrotic honeycombing and no ground glass is probably, well, we know it's progressive pulmonary fibrosis, but it might not be as amenable in addition to the treatment to immune suppression. Whereas NSIP like really quite inflamed the way some of our acute myositis patients are, is probably very responsive in many to immune suppression.

But I think there's a whole bunch of in betweens and so therefore I agree that there's probably a season or a time to treat with sometimes both or treat with one and the other one quickly depending on what direction you're going. And I don't think that imaging as as black and white, pun intended, as we think it might be.

Elena, do you have a comment on this? Question for you is going be, you can comment on this, but, we're considering response to narendoma last based on having an autoimmune disease, and then also the time to diagnosis. Is it right to do that by diagnosis or should we be considering responsiveness according to pathology, whether they're UIPs or NSIPs or otherwise, including mixed pictures etc?

Yeah. You know, that's a great question. I mean, there were a number of abstracts at the meeting that really kind of indicated that, RA, even UIP needs to be treated with immunosuppression, would be amenable to immunosuppression. So I think autoimmune ILD UIP is a different beast than some of the other UIPs that we might encounter. So it might it might be okay, actually.

I mean, maybe not... I think it is appropriate to do it by diagnosis because we are seeing more and more that it matters in terms of... I mean, the end result might look similar on imaging or what have you, but how they're getting there and maybe even the processes that are continuing might be different. I will say also it's it's good to kind of know when the neuroendomast was started. I mean, we so frequently are wondering, like, at what point should we add something?

Should this be a stepwise therapy? Should we be throwing everything at the patients at the same time? And I think if we can answer that question with our studies, that would be very clinically useful.

Okay. Derek, what was your second one?

Second one was abstract six forty five by Jones et al. Was looking at mortality from time of idiopathic inflammatory myopathy diagnosis associated with ILD. So, it was a relatively small cohort out of Vanderbilt of forty one patients newly diagnosed with myositis ILD and looking at specific outcomes over a two year period. At baseline, forty three percent of these patients were on supplemental oxygen. Many of them were hospitalized.

So, this was a relatively sick cohort of patients. And looking at two year outcomes, fifteen percent of patients died in the two year follow-up period at a median time of eight and a half months. Nine point eight percent of these patients required lung transplantation and that occurred around thirteen months. Smaller But portion of the patients who survived, only thirteen point three percent of survivors had progression while half of the survivors, they actually had improvement and improvement in their cohort was greater than ten percent predicted FVC. It looked like all these patients who were survivors, they benefited from immunotherapy of whatever was selected in this observational cohort.

There was improvements regardless of what their baseline oxygen status was if they required supplemental or not. I think this agrees with what we know about myositis ILD is that a lot of times the severe cases are front loaded. These patients usually require aggressive management upfront, but the people who do seem to respond to therapy, there is improvement and there is the chance for survival and long term improvement.

Do we know what the autoantibody profile was on the ILD? How many of those were MDA-5s?

It was not cited in the abstract. That's definitely information I would like to know. Yes, we don't know the MDA-five's antisynthetase, not in this abstract that I saw.

My question to all of you then is, is this typical of myositis associated ILD? My eyes got big with the numbers of fifteen percent getting worse, nine percent death and transplant, that's twenty four percent doing really badly. When I started out by saying, if there's a subgroup of ILD that might do well, it might be the myositis people, but maybe there's a subset within myositis is gonna do really poorly, but there's a lot that can turn around. How should I read this? Elena, what do you think?

I think there was a selection bias. So most of these patients were already very, very sick at baseline. I mean, I see a lot of cases, if we can catch them and we can immunosuppress them, I would say this sounds about right for those really sick patients at baseline. But I I haven't heard, what kind of immunosuppression they were on. I just heard, immunosuppression.

I don't know if they provided that detail, Derek. But, yeah, this is, I would say this is pretty typical. And a lot of times, people require triple, quadruple therapy upfront to stabilize them. Jan, that's

what you see too?

It is unfortunately. So early, great for a lot of them, they're caught early. They're treated fairly aggressively. Steroids and I agree triple therapy if they have really quite obvious either MDA five or quite obvious ILD at the beginning. The problem is some of these people get over that hump and smolder and years later, not necessarily MDA five, but JO1s, other synthetase, etc.

Rows fit row 52. And later there, they become, I'll call it far higher mortality risk on their lungs where almost like it got away from me under the radar screen.

Yeah. Alright. That's really exciting. Janet, you had a few that you wanted to talk about. Go go ahead.

Go right ahead.

Right. So the first one... So I'm gonna change the order of what I'll I'll talk about because abstract fifteen eighty six is yet another myositis, dermatomyositis with ILD. So this is a study looking at, I'll call it hypothesis generating, probably not hypothesis testing because the VALOR VALOR study was Beprosidinib and to remind people that was a positive phase two to three RCT in dermatomyositis and Bepro is a, they call it Tick two, Jack one, but I would like to say Jack one, tick two because that's how all the other terminology is. So maybe they're stressing it's more tick than Jack, I don't know.

But anyway, it's a Tick two, Jack one drug. And this was so the phase two, three study had two forty one people with dermatomyositis and of that twenty percent or forty seven people had baseline ILD. Now, if you're really severe, you probably wouldn't put someone in a placebo controlled trial because you're failing background immune suppression. So we'll call it ILD that they're bad enough to get in a trial, but maybe not the most severe. However, this is a fifty two week study.

What happens? You either on fifteen milligrams of Bepricidinib, you get one percent improvement over a year in FVC. So probably stable to no change on thirty milligrams, same thing, 0% change, but placebo and only one year went down by a mean FVC of three percent predicted and you go 3% no big deal. But it is that means some people would have met criteria for rapid progression. We don't have all the results, but I think that this is something that makes me interested to say, you know, this might be a really good drug.

We've had a lot of ideas of JAK inhibitors helping ILD in some patients, but no RCT looking specifically at it. And let's be fair, this is only forty seven patients, a subset analysis, but I think there might really be something there. So that's why I chose it.

Yeah, I think this is novel. You know, the VALOR study was published in New England Journal this past summer. I believe in The United States that this drug is poised for FDA approval sometime in the very near future. Would be join IVIG as one of the few approved therapies for myositis, in this case dermatomyositis. I think this is really exciting.

The question is, how is our treatment algorithm going to change for myositis? I think this kind of information might make you want to go down this path as opposed to using methotrexate. When you use methotrexate or other drugs that... Mean, I one of my favorite drugs in dermatomyositis polymyositis is leflinomide, also implicated in causing ILD. I don't believe that.

Methotrexate, I don't believe causes ILD, but you don't wanna give those drugs when you've got a lung thing that's on the table. Maybe you're you're jumping more to IVIG and, JAK1 TYK2 drug. But, Derek, what do you think of this data?

Well, I I think something to, keep in mind with this trial too is that patients could still be on background immunosuppression. If a patient had ILD and was on mycophenolate, they could continue their mycophenolate. If they're on methotrexate, they could continue methotrexate. So, I think that this data is important because it also tells us a little bit on the side that we're combining these drugs and it's potentially efficacious. Gives us some information about the safety of doing that.

I don't think the subgroup analysis necessarily looked at who was on more agents than that. But I think that's an important takeaway too, that there's a lot of combination therapy going on this, myositis ILD population.

So Elena, this goes to a little bit to your point about in some of these subsets like myositis, there's a role for immunosuppression, especially early on. What do you think?

Yeah. I I absolutely agree. You know, in terms of how it changes the algorithm, I believe it's already approved because... I mean, unless... Yeah.

I... It's it's already approved because I put a patient on it just recently. And it was... I mean, I'm glad you see these results and specifically ILD because, I mean, that's that's kind of what I... What the goal is for me most of the time is to treat the the ILD along with other manifestations in the patient.

So I think it will it will change the way that we approach these patients. Definitely.

And that can only be a good thing. Janet, what was your second one?

Okay. So this one, sometimes people, like, start snoozing when I talk about biomarkers, but I'm gonna tell you the results, then I'm gonna tell you why I chose them. So this was the poster zero zero two five. So this was an abstract that looked at accelerated senescence in being increased in the SARD ILD patients. And basically they also looked at that it might, might because it's hard to know when the timeframe that they look that it could also be that if you have high senescence changes that you could have more progression to fibrotic lung disease.

And what it showed this was a basic science kind of study. So what it showed that there's epithelial remodeling that's like negative, it's not helpful and it's from DNA damage. So this senescence was far higher and the lung biopsies and stuff like that with SARD ILD patients and say a lung that was looked at for a different reason. So now I'm gonna tell you why I looked because I had a meeting with a lot of pulmonologists there and they were talking about short telomeres and that that is apparently a really big deal as a risk in maybe one in ten patients with IPF. And I didn't know really anything about that.

I knew that lots of our diseases you could have accelerated aging, many diseases that we see. So it kind of took me down a rabbit hole to at what data are there on progression of NSIP in our patients or a non fibrotic phenotype into a fibrotic phenotype. And a lot of the risk factors for ILD depending on the disease, high CRP for instance, etc, also elevated when a patient seems to be transitioning. I say seems to be because it's not overnight that you don't do a CT every day, it might be over a year, but high, you know, some of the antibodies associated with ILD in each disease are also associated with more progression to fibrosis, same with CRP and same with a few other markers that we don't look at that often. So I thought the senescence thing might kind of help tie it together that if things are readily available, would I be the one to order on my patients to say, I lose sleep over you at night?

I wouldn't tell them that that way, but should I worry about you or shouldn't I worry about you? So it's just a little abstract that might lead to bigger things down the road.

Elena, you've done a lot of research on telomeres. Tell us where that stands right now in our understanding of ILD and risk.

Yes, telomeres are really, really hot topic. It's a little bit hard sometimes to really know whether senescence comes first, telomere second, or telomeres first, senescence second, or both are happening at the same time. But there is definitely a lot of new information coming in that short telomere links and variance in genes that maintain the telomeres really play a big role, and not just in idiopathic pulmonary fibrosis IPF, but we are seeing it in other types of ILD as well. There was a study that was done a few years ago out of UT Southwestern, where Chad Newton and others looked at how the telomere lengths was predicting survival. And they were looking at SARDA LD, CTD LD, IPF, and actually IPAF, interstitial pneumonia without immune features, they did find that those who had short telomeres tended to have more kind of UIP pattern, but also a lot more progression and earlier death.

But the caveat is that SARDA ILD didn't have such a high prevalence of short telomeres, so it's still there. We know that there is more short telomeres in RA ILD and scleroderma ILD, but perhaps it is just not as enriched sometimes, as in some cohorts of kind of less classifiable or more kind of idiopathic, if you will, ILD.

It's a little bit, elsewhere in the meeting. I think maybe on Roundup, Artie Cavanaugh and I talked about, clonal hematopoiesis being a feature of, that colors the story behind the GCA and vasculitis. And, these are, looking at basically mutant clones and clonal hematopoiesis or CHIP, is associated with aging like telomere changes, but also associated with, risk and, risk of relapse in vasculitis. Looks like some of the biomarkers are making sense in that they're coming from aging, coming from breakdown, and we tend to get these diseases as we get older. It makes some sense to me, but Janet, you think this is going to become part of the workup?

So I'm going to say yes and no. The yes is the people progressive pulmonary fibrosis expert sites are doing it more for research. Think the IPF, some of them are doing it commercially, but they don't know what to do with the results. But I think again, if I have a person who has maybe just a little bit of fibrotic change and they're healthy, like they have their, I'll call their SARD under control, I really need the crystal ball a little bit, a decent enough biomarker that says they might progress or not because some of them, as I say, they go under the radar screen. So the short answer is in clinical care today, no.

Will we get a little biomarker panel or a big biomarker panel that is more predictive of intervening earlier? Wouldn't it be great if we got reversibility? You know, are we gonna send these people all off for CAR T? Probably not because it's not feasible. So bottom line is I think that more will come and I think that right now it's not really too helpful for us in the clinic, but it's helpful in research and I think more ideas will come from it.

You know, think that tend to be very old school on a lot of new interventions and studies and whatnot in that. I like to be pragmatic. But I will say that when it comes to scary disease, and then by under the category of scary diseases, systemic sclerosis and ILD and MDA five myositis, I I would be... Tend to be liberal in my ordering of, you know, cutting edge, diagnostic tests that can be used to prognosticate or stage. If only so that I can have an intelligent conversation with, Eleni Jones at the at the Mayo Clinic, you know, who is gonna be able to tell me what she knows about all the information I've gathered.

I do that all the time with vasculitis. I call the, you know, the mavens at the Cleveland Clinic. You know? I call Janet on what to do with a scleroderma who is scaring me, and I don't really know what the best first or next intervention is gonna be. I I think that it does make sense to, at times, to be aggressive.

So, on the other hand, you know, there's a lot of research that is... Was shown at ACR that the question is how impactful, how much utility it has. I'll I'll close with an abstract two eight eight two by Vencat et al, which includes Jeff Sparks group at the Brigham Mass General, and they did a sort of a discovery and validation study on autoantibodies in patients with RA with and without ILD. They had RA controls, IPF controls, healthy controls, and they looked to see, you know, what antibodies could be used. They did a, sort of a wide breadth of antibodies, and they found that, you know, in in...

When they looked at all their RA ILD cases, over three quarters of them had at least one RA on an... Autoantibody. And they looked at, rheumatoid factor IgA, IgM, CCP, IgA, and IgG, CARP antibodies IgG, and PAD III IgG antibodies. And so that a lot more tests than I would normally get. But obviously, the CCP, it could be driven by citrullinization that you get with PADI antibodies, that could be reflective of that.

Same thing for homosynchronization with CARP. And they did find that certain of these antibodies indicative of carbamylation and citrullization were very much involved in the pathogenesis of RAILD. Both the suggested by the the, discovery set and then validated in the validation subset. And that's important because the question, I I think is that if RA is a disorder of mucosa, and it's a mucosal hypothesis to RA, and that the lung is the point of attack, it's not surprising that not only will you get autoantibodies that may be pathogenic leading to the clinical state of RA, but that in what goes on in the lung, maybe, an early entry into a cascade you can't stop, is interstitial lung disease, which is deadly in RA. So I like the story of multiple autoantibodies showing up, but does any of this change your thinking, Elena?

I guess not really, not yet. I mean, I I deal a lot with the traditional pneumonia without immune features. Right? So I I see a lot of ILD with autoantibodies, and some of those autoantibodies can be really kind of not specific and not necessarily fitting any other, specific disease. And for me, I guess, autoantibodies have long been just like a marker of of some inflammation, some autoimmunity that is going on.

So not not too much. I will say a caveat. Myositis specific antibodies might be different, but in terms of those RA antibodies that you listed, not not yet.

Yeah. I I I used to look at multiple autoantibodies in someone with lung disease, especially, what we think is immune mediated lung disease as being nonsensical, you know, because you're stimulating all those, you know, immunologically active alveoli and their macrophages to just run amok and, you know, with alpha interferon, you know, driving, you know, a lot of auto and IL 10 and many other signals driving autoantibody production. Janet, would you think of these autoantibodies, the multiplicity of them as biomarkers in RA lung?

Well, they maybe are. Mean, it was a really interesting presentation and I think the bottom line is it really important for research. Am I going to, in the next patient that I'm worried about because they're older, male, smoke, bad disease in the first twenty years before we have really good drugs or treating to target? And am I going to start looking or am I going to say, you're at risk, I'm gonna follow you carefully because we don't routinely do carp or patty and all that stuff. So I think it's interesting and I think it might be even somewhat mechanistic as you mentioned, like the mucosal hypothesis that you're breaking down a barrier possibly, etc.

But I think right now for my patients with RA, I am not screening everyone other than listening to the bases of the lungs, like I said earlier, listen for crackles. But I'm screening and I'm investigating wherever I think it's appropriate or if I'm kinda concerned. We had a patient today come in who had very, very mild clubbing that we didn't see last time, and we're gonna investigate. We don't know why.

Yeah. Find the clues, chase down the clues. I wanna thank our panel for an excellent discussion on a tough and very important subject of interstitial lung disease. They were out there looking at all the posters and all the oral presentations, and I think we got a glimpse of what was important from the meeting. Elena, Derek, and Janet, thanks so much.

Tune in for more on these panel discussions.

Alright, everyone.

Thank you. Thanks.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×